Therapy Areas: Inflammatory Diseases
RedHill Biopharma finds encouraging data from the Oral Opaganib Phase 2 study in COVID-19 patients
22 June 2021 -

Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq:RDHL) on Monday provided the data from its Phase 2 positive safety and efficacy data for oral opaganib in 40 hospitalised patients in the US with COVID-19 pneumonia at World Microbe Forum (WMF) 2021.

According to the company, Opaganib (Yeliva, ABC294640) is a novel and patented selective inhibitor of sphingosine kinase 2 (SK2) that is administered orally, with a unique effect demonstrated of dual anti-inflammatory and antiviral activity that targets a component of the host cell of viral replication, potentially minimizing the likelihood of viral resistance.

The company said the results and post hoc analysis of data from the phase 2 study were presented through a poster titled Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlledPhase 2A Study, in AdultSubjectsHospitalizedwith SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 ).

About 86.4% of patients receiving the company's opaganib treatment were discharged from the hospital on day 14, from 55.6% of patients receiving placebo. About 81.8% of patients treated with opaganib achieved a two point improvement on the WHO Ordinal Scale, over 55.6% of patients who were part of the placebo group, achieved with a mean time of six days compared to seven and half days, respectively.

Login
Username:

Password: